Paul Tudor Jones's MYGN Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 44,820 shares of Myriad Genetics, Inc. (MYGN) worth $275,643, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 44 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in MYGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2013, adding 92,142 shares. Largest reduction occurred in Q1 2014, reducing 126,537 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Myriad Genetics (MYGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Myriad Genetics (MYGN) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +44,820 | New Buy | 44,820 | $6.15 |
| Q3 2025 | -45,321 | Sold Out | 0 | $0.00 |
| Q2 2025 | -381 | Reduce 0.83% | 45,321 | $5.31 |
| Q1 2025 | -4,233 | Reduce 8.48% | 45,702 | $8.87 |
| Q4 2024 | +33,937 | Add 212.13% | 49,935 | $13.71 |
| Q3 2024 | +15,998 | New Buy | 15,998 | $27.39 |
| Q1 2024 | -14,856 | Sold Out | 0 | $0.00 |
| Q4 2023 | +4,500 | Add 43.45% | 14,856 | $19.14 |
| Q3 2023 | -34,323 | Reduce 76.82% | 10,356 | $16.04 |
| Q2 2023 | +1,341 | Add 3.09% | 44,679 | $23.18 |
| Q1 2023 | +5,413 | Add 14.27% | 43,338 | $0.02 |
| Q4 2022 | -2,316 | Reduce 5.76% | 37,925 | $0.01 |
| Q3 2022 | +3,121 | Add 8.41% | 40,241 | $19.09 |
| Q2 2022 | -4,651 | Reduce 11.13% | 37,120 | $18.16 |
| Q1 2022 | +27,899 | Add 201.12% | 41,771 | $25.21 |
| Q4 2021 | +13,872 | New Buy | 13,872 | $27.61 |
| Q2 2021 | -55,845 | Sold Out | 0 | $0.00 |
| Q1 2021 | -34,856 | Reduce 38.43% | 55,845 | $30.44 |
| Q4 2020 | +36,234 | Add 66.52% | 90,701 | $19.78 |
| Q3 2020 | -21,797 | Reduce 28.58% | 54,467 | $13.04 |
| Q2 2020 | +76,264 | New Buy | 76,264 | $11.34 |
| Q3 2019 | -100,707 | Sold Out | 0 | $0.00 |
| Q2 2019 | -9,754 | Reduce 8.83% | 100,707 | $27.78 |
| Q1 2019 | +34,352 | Add 45.14% | 110,461 | $33.20 |
| Q4 2018 | +20,924 | Add 37.92% | 76,109 | $29.06 |
| Q3 2018 | +13,939 | Add 33.79% | 55,185 | $46.01 |
| Q2 2018 | +24,439 | Add 145.41% | 41,246 | $37.36 |
| Q1 2018 | +16,807 | New Buy | 16,807 | $29.57 |
| Q2 2017 | -19,700 | Sold Out | 0 | $0.00 |
| Q1 2017 | -27,333 | Reduce 58.11% | 19,700 | $19.19 |
| Q4 2016 | +15,291 | Add 48.17% | 47,033 | $16.67 |
| Q3 2016 | +17,575 | Add 124.06% | 31,742 | $20.57 |
| Q2 2016 | -8,224 | Reduce 36.73% | 14,167 | $30.63 |
| Q1 2016 | +1,005 | Add 4.70% | 22,391 | $37.43 |
| Q4 2015 | +10,112 | Add 89.69% | 21,386 | $43.16 |
| Q3 2015 | +11,274 | New Buy | 11,274 | $37.52 |
| Q1 2015 | -6,518 | Sold Out | 0 | $0.00 |
| Q4 2014 | -1,458 | Reduce 18.28% | 6,518 | $34.06 |
| Q3 2014 | -4,857 | Reduce 37.85% | 7,976 | $38.62 |
| Q2 2014 | +5,928 | Add 85.85% | 12,833 | $38.88 |
| Q1 2014 | -126,537 | Reduce 94.83% | 6,905 | $34.18 |
| Q4 2013 | +92,142 | Add 223.10% | 133,442 | $20.98 |
| Q3 2013 | +3,900 | Add 10.43% | 41,300 | $23.51 |
| Q2 2013 | +37,401 | Add 0.00% | 37,400 | $26.87 |
Paul Tudor Jones's Myriad Genetics Investment FAQs
Paul Tudor Jones first purchased Myriad Genetics, Inc. (MYGN) in Q2 2013, acquiring 37,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Myriad Genetics, Inc. (MYGN) for 44 quarters since Q2 2013.
Paul Tudor Jones's largest addition to Myriad Genetics, Inc. (MYGN) was in Q4 2013, adding 133,442 shares worth $2.8 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 44,820 shares of Myriad Genetics, Inc. (MYGN), valued at approximately $275,643.
As of the Q4 2025 filing, Myriad Genetics, Inc. (MYGN) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Myriad Genetics, Inc. (MYGN) was 133,442 shares, as reported at the end of Q4 2013.